Zevra Therapeutics Inc (NASDAQ: ZVRA) is 33.59% higher on its value in year-to-date trading and has touched a low of $4.20 and a high of $9.76 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ZVRA stock was last observed hovering at around $8.58 in the last trading session, with the day’s gains setting it 0.01%.
Currently trading at $8.59, the stock is -3.35% and -1.45% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.14 million and changing 0.12% at the moment leaves the stock 29.91% off its SMA200. ZVRA registered 78.57% gain for a year compared to 6-month gain of 90.63%. The firm has a 50-day simple moving average (SMA 50) of $8.7028 and a 200-day simple moving average (SMA200) of $6.60015.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -8.71% loss in the last 1 month and extending the period to 3 months gives it a 15.97%, and is 3.18% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.80% over the week and 4.36% over the month.
Zevra Therapeutics Inc (ZVRA) has around 69 employees, a market worth around $459.03M and $24.79M in sales. Profit margin for the company is -342.63%. Distance from 52-week low is 104.52% and -11.99% from its 52-week high. The company has generated returns on investments over the last 12 months (-65.75%).
with sales reaching $8.78M over the same period.The EPS is expected to shrink by -46.06% this year, but quarterly earnings will post -25.84% year-over-year. Quarterly sales are estimated to shrink -33.60% in year-over-year returns.
Zevra Therapeutics Inc (ZVRA) Top Institutional Holders
The shares outstanding are 53.23M, and float is at 53.08M with Short Float at 7.67%.
Zevra Therapeutics Inc (ZVRA) Insider Activity
The most recent transaction is an insider purchase by Watton Corey Michael, the company’s Director. SEC filings show that Watton Corey Michael bought 500 shares of the company’s common stock on Oct 11 ’24 at a price of $7.92 per share for a total of $3958.0. Following the purchase, the insider now owns 1500.0 shares.
Zevra Therapeutics Inc disclosed in a document filed with the SEC on Jul 17 ’24 that Clifton R. LaDuane (CFO & Treasurer) bought a total of 2,000 shares of the company’s common stock. The trade occurred on Jul 17 ’24 and was made at $6.77 per share for $13540.0. Following the transaction, the insider now directly holds 18469.0 shares of the ZVRA stock.
Still, SEC filings show that on Jul 16 ’24, Anderson Thomas (Director) acquired 10,000 shares at an average price of $6.81 for $68065.0. The insider now directly holds 20,000 shares of Zevra Therapeutics Inc (ZVRA).
